Clinical trial · no report yet · Phase 3
NCT03867084
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- NCT03867084 ↗
- Completed
- Merck Sharp & Dohme LLC
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 11 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab; Placebo
- Arms
- Pembrolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 959
- Primary outcomes
- Recurrence-Free Survival (RFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 28, 2019
- Primary completion
- Mar 20, 2025
- Results posted
- Yes
- Registry record
- NCT03867084 · updated Apr 24, 2026
Publications
linked from the registry- Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807. PubMed 35421228